Click Here to Register »

Technology Sponsors

Credence MedSystems
Insulet Corporation
Salvona Technologies
Sensile Medical

Media Partners

On Drug Delivery
BioPharm Insight
Bloomberg Brief
Can Biotech
Clinical Informatics News
Drug Development & Delivery
Fierce Drug Delivery
Larta Institute
Life Science Leader
Massachusetts Life Sciences Center
MCD Group
Medical News Today
Medtech Boston
Technology Networks


  • Preliminary Early Agenda

  • Conference Chair

    Conference Chair

    Barbara Lueckel, PhD
    Head of Research & Technologies Partnering, Roche

  • Opening Keynote Address on Nanotechnology

    Opening Keynote Address on Nanotechnology

    Robert Langer, PhD
    David H. Koch Institute Professor, MIT

  • Licensing Drug Delivery Technologies for Oncology Therapeutics

    In this panel, we will hear from business development and licensing executives regarding current level of interest in drug delivery technologies for pipeline and launched drugs.

    • Licensing improved formulations of off-patent cancer drugs vs. enabling platform technologies for NCEs
    • Criteria used to evaluate novel oncology drug delivery systems
    • What stage and type of data is most attractive to pharmaceutical partners?
    • Types of formulations and technology platforms actively sought:
      • Nanotechnology-based/Nanomedicine
      • Antibody drug conjugates
      • Sustained release depots/implants
    • Structuring partnerships – platform vs. product licenses, option-based agreements, regional deals

    Barbara Lueckel, PhD
    Head of Research & Technologies Partnering, Roche

    Neela Patel, PhD
    Director, Licensing-Search and Evaluation, Abbvie

    Denis Patrick, PhD
    Executive Director, Head External R&D Innovation, Oncology Research Unit, Pfizer

    Vahe Bedian, PhD
    Director, Oncology External Projects, AstraZeneca

  • Can RNA-based Therapeutics Really Deliver?

    Despite the therapeutic promise of RNA therapeutics, efficient and safe drug delivery remains a significant challenge.   These therapeutics tend to have unfavorable physicochemical properties including negative charges, large molecular weight and size, and instability.   A number of carrier systems are being developed for RNA therapeutics, including polymers, lipids, and conjugates, but selection of the delivery system depends on the therapeutics properties, type of target cells and the desired delivery route.   This panel will discuss:

    • Key hurdles related to delivery of RNA therapeutics: siRNA, mRNA, RNAi
    • Delivery strategies and examples of recent successes
    • Collaborative approaches/models that are working
    • Commercialization prospects given low success rate of RNA drugs to-date

    Jessica Ballinger
    Senior Director, Protein Pharmaceutical Development, Biogen Idec

  • Partnering Meetings – 45 minutes

  • Sanofi Drug Delivery Case Study

    Paul Jansen
    VP, Medical Device Development, Sanofi

  • Technology Spotlight

    Sponsored by:
    3M Drug Delivery Systems

  • Drug Delivery Presentations in Three Tracks

    Track OneNon-Injectable Formulation Technologies

    Track TwoInjectable Formulation Technologies

    Track ThreeDrug Delivery Device Technologies

    If you are interested in presenting in one of the tracks, please contact Meredith Sands at

  • Partnering Meetings – 45 minutes


  • Preliminary Early Agenda

  • Conference Chair

    Conference Chair

    Barbara Lueckel, PhD
    Head of Research & Technologies Partnering, Roche

  • Industry Keynote

    To be announced.

  • Nanotechnology Panel

    Omid Farokhzad, MD
    Associate Professor, Harvard Medical School

  • Large Volume Drug Delivery – Are Patch Pumps the Answer?

    Due to the increasing need for improved parenteral delivery of high dose pharmaceuticals, especially biologics, a number of new wearable devices have been developed, such as patch pumps and bolus injectors. These devices enable self-administration and eliminate the need for multiple injections or infusions. This panel will discuss the current generation of wearable injection devices and the opportunities and challenges that lie ahead.

    • Key drawbacks of current devices – what should next generation devices address?
    • Beyond insulin, will patch pumps be cost-effective for other drugs such as mAbs?
    • How does the size of the device affect patient acceptability?
    • Implementing acceptance of wearable technology
    • Selecting the appropriate device, and device manufacturer-partner

    Anand Subramony
    VP, Drug Delivery & Device Development, Biopharmaceutical Development, MedImmune

    Christopher Coletta, PhD
    Director of Drug Delivery Strategy & Innovation, Amgen

    David Haase
    Senior Manager, Device Development, Genentech

    Andrew Hamer, MD
    VP, Medical Affairs, Capricor Therapeutics

  • Partnering Meetings – 45 minutes

  • Improving Drug Delivery to the Back of the Eye

    There is an increasing need to successfully treat posterior eye diseases such as age-related macular degeneration, glaucoma, and diabetic retinopathy.   Drug delivery to the back of the eye is challenging not only because of the anatomy of the eye and associated static and dynamic barriers, but also due to the growth of biologic therapeutics, and the challenges of delivering and stabilizing these more complex, large molecules.   This panel will discuss goals and challenges of delivery, types of delivery systems showing promise for more effective delivery, and the benefits of collaborating in this space.

    James J. Cunningham, PhD
    Director, Ocular Drug Delivery, Allergan

  • Company Spotlights

    In this session, we highlight three companies that discuss their partnering philosophy, current needs and scouting interests as related to drug delivery.

    Christopher Coletta, PhD
    Director of Drug Delivery Strategy & Innovation

    Sanofi-Genzyme BioVentures
    Ann DeWitt, PhD
    Senior Director of Investments

  • DDS Technology Soapbox@PODD sponsored by Pfizer

    Julia Rashba-Step, PhD
    Senior Director, Novel Delivery Technologies, Pfizer BioTherapeutics

    This session features five-minute talks on cutting-edge technologies, inventions and ideas. The PODD Soapbox section is open to start-up entrepreneurs, inventors, licensing officers and university researchers.

    If you are interested in presenting on the Soapbox, please contact Meredith Sands at